(Q44632270)

4 December 2017

title

Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction (English)

1 reference

4 December 2017

Kazuya Omoto

1

1 reference

4 December 2017

Kazunari Tanabe

2

1 reference

4 December 2017

Tadahiko Tokumoto

3

1 reference

4 December 2017

Hiroaki Shimmura

4

1 reference

4 December 2017

Hideki Ishida

5

1 reference

4 December 2017

Hiroshi Toma

6

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

4 December 2017

27 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14578748

25 March 2024

1 reference

4 December 2017

volume

76

1 reference

4 December 2017

issue

8

1 reference

4 December 2017

page(s)

1170-1174

1 reference

Is chronic renal transplant rejection a non-immunological phenomenon?

4 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Chronic transplant rejection

25 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Nephron supply is a major determinant of long-term renal allograft outcome in rats

25 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

High Survival Rates of Kidney Transplants from Spousal and Living Unrelated Donors

25 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study

25 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Proteinuria after renal transplantation affects not only graft survival but also patient survival

25 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group

25 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

25 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

25 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

25 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease

25 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass

25 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure

25 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats

25 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116

25 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats

25 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Hypertension after renal transplantation

25 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Enalapril-associated anemia in renal transplant recipients treated for hypertension

25 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Treatment with losartan in kidney transplant recipients with posttransplant erythrocytosis

25 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Losartan and renal transplantation

25 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells

25 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis

25 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1

25 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts

25 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection

25 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy

25 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/01.TP.0000073615.57523.AC

25 March 2024

Identifiers

1 reference

4 December 2017

1 reference